VYNE Therapeutics Inc. (VYNE) Financials

VYNE Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 97.7 million 9.0 million
2023-09-30 19.3 million 7.8 million
2023-06-30 25.0 million 7.7 million
2023-03-31 35.3 million 8.8 million

VYNE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -5.1 million 710000
2023-09-30 -5.2 million 863000
2023-06-30 -9.6 million 876000
2023-03-31 -5.5 million 856000

VYNE Net Income

No data available :(

VYNE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 93.3 million - 214000
2023-09-30 15.4 million - -
2023-06-30 20.6 million - -
2023-03-31 30.2 million - -

VYNE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 3.1 million
2023-09-30 3.3 million
2023-06-30 3.3 million
2023-03-31 3.3 million

VYNE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 3.0 million 13.4 million 9.5 million
2023-09-30 - 3.3 million 3.0 million -
2023-06-30 - 7.2 million 3.2 million -
2023-03-31 - 2.7 million 3.2 million -

VYNE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 76000 -
2023-09-30 114000 -
2023-06-30 135000 -
2023-03-31 99000 -

VYNE

Price: $2.53

52 week price:
1.67
8.73

Earnings Per Share: -2.72 USD

P/E Ratio: -0.23

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 68900

Market Capitalization: 39.1 million

Links: